Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 98

1.

SS1P Immunotoxin Induces Markers of Immunogenic Cell Death and Enhances the Effect of the CTLA-4 Blockade in AE17M Mouse Mesothelioma Tumors.

Leshem Y, King EM, Mazor R, Reiter Y, Pastan I.

Toxins (Basel). 2018 Nov 14;10(11). pii: E470. doi: 10.3390/toxins10110470.

2.

Combining Local Immunotoxins Targeting Mesothelin with CTLA-4 Blockade Synergistically Eradicates Murine Cancer by Promoting Anticancer Immunity.

Leshem Y, O'Brien J, Liu X, Bera TK, Terabe M, Berzofsky JA, Bossenmaier B, Niederfellner G, Tai CH, Reiter Y, Pastan I.

Cancer Immunol Res. 2017 Aug;5(8):685-694. doi: 10.1158/2326-6066.CIR-16-0330. Epub 2017 Jul 3.

3.

Major-histocompatibility complex harnessing and lymphocytic recruitment: a new tool for glioblastoma multiforme immunotherapy.

Cohen-Inbar O, Reiter Y, Zaaroor M.

J Neurosurg Sci. 2017 Aug;61(4):422-428. doi: 10.23736/S0390-5616.16.03755-3. Epub 2016 Jun 15. Review.

PMID:
27303860
4.

Recruitment of Oligoclonal Viral-Specific T cells to Kill Human Tumor Cells Using Single-Chain Antibody-Peptide-HLA Fusion Molecules.

Noy R, Haus-Cohen M, Oved K, Voloshin T, Reiter Y.

Mol Cancer Ther. 2015 Jun;14(6):1327-35. doi: 10.1158/1535-7163.MCT-14-0467. Epub 2015 Apr 7.

5.

A novel host-proteome signature for distinguishing between acute bacterial and viral infections.

Oved K, Cohen A, Boico O, Navon R, Friedman T, Etshtein L, Kriger O, Bamberger E, Fonar Y, Yacobov R, Wolchinsky R, Denkberg G, Dotan Y, Hochberg A, Reiter Y, Grupper M, Srugo I, Feigin P, Gorfine M, Chistyakov I, Dagan R, Klein A, Potasman I, Eden E.

PLoS One. 2015 Mar 18;10(3):e0120012. doi: 10.1371/journal.pone.0120012. eCollection 2015.

6.

Functional comparison of engineered T cells carrying a native TCR versus TCR-like antibody-based chimeric antigen receptors indicates affinity/avidity thresholds.

Oren R, Hod-Marco M, Haus-Cohen M, Thomas S, Blat D, Duvshani N, Denkberg G, Elbaz Y, Benchetrit F, Eshhar Z, Stauss H, Reiter Y.

J Immunol. 2014 Dec 1;193(11):5733-43. doi: 10.4049/jimmunol.1301769. Epub 2014 Oct 31.

7.

On the limited recognition of inorganic surfaces by short peptides compared with antibodies.

Artzy-Schnirman A, Abu-Shah E, Dishon M, Soifer H, Sivan Y, Reiter Y, Benhar I, Sivan U.

J Pept Sci. 2014 Jun;20(6):446-50. doi: 10.1002/psc.2636. Epub 2014 Apr 15.

PMID:
24733719
8.

HLA-DRα1 constructs block CD74 expression and MIF effects in experimental autoimmune encephalomyelitis.

Meza-Romero R, Benedek G, Yu X, Mooney JL, Dahan R, Duvshani N, Bucala R, Offner H, Reiter Y, Burrows GG, Vandenbark AA.

J Immunol. 2014 May 1;192(9):4164-73. doi: 10.4049/jimmunol.1303118. Epub 2014 Mar 28.

9.

Antigen-dependent integration of opposing proximal TCR-signaling cascades determines the functional fate of T lymphocytes.

Wolchinsky R, Hod-Marco M, Oved K, Shen-Orr SS, Bendall SC, Nolan GP, Reiter Y.

J Immunol. 2014 Mar 1;192(5):2109-19. doi: 10.4049/jimmunol.1301142. Epub 2014 Jan 31.

10.

Antigen-specific immunomodulation for type 1 diabetes by novel recombinant antibodies directed against diabetes-associates auto-reactive T cell epitope.

Dahan R, Gebe JA, Preisinger A, James EA, Tendler M, Nepom GT, Reiter Y.

J Autoimmun. 2013 Dec;47:83-93. doi: 10.1016/j.jaut.2013.08.009. Epub 2013 Oct 3.

PMID:
24090977
11.

MUC1 is a potential target for the treatment of acute myeloid leukemia stem cells.

Stroopinsky D, Rosenblatt J, Ito K, Mills H, Yin L, Rajabi H, Vasir B, Kufe T, Luptakova K, Arnason J, Nardella C, Levine JD, Joyce RM, Galinsky I, Reiter Y, Stone RM, Pandolfi PP, Kufe D, Avigan D.

Cancer Res. 2013 Sep 1;73(17):5569-79. doi: 10.1158/0008-5472.CAN-13-0677. Epub 2013 Jul 18.

12.

Topical vaccination with functionalized particles targeting dendritic cells.

Baleeiro RB, Wiesmüller KH, Reiter Y, Baude B, Dähne L, Patzelt A, Lademann J, Barbuto JA, Walden P.

J Invest Dermatol. 2013 Aug;133(8):1933-41. doi: 10.1038/jid.2013.79. Epub 2013 Feb 20.

13.

Immunoglobulin-like transcript receptors on human dermal CD14+ dendritic cells act as a CD8-antagonist to control cytotoxic T cell priming.

Banchereau J, Zurawski S, Thompson-Snipes L, Blanck JP, Clayton S, Munk A, Cao Y, Wang Z, Khandelwal S, Hu J, McCoy WH 4th, Palucka KA, Reiter Y, Fremont DH, Zurawski G, Colonna M, Shaw AS, Klechevsky E.

Proc Natl Acad Sci U S A. 2012 Nov 13;109(46):18885-90. doi: 10.1073/pnas.1205785109. Epub 2012 Oct 29.

14.

A novel regulatory pathway for autoimmune disease: binding of partial MHC class II constructs to monocytes reduces CD74 expression and induces both specific and bystander T-cell tolerance.

Vandenbark AA, Meza-Romero R, Benedek G, Andrew S, Huan J, Chou YK, Buenafe AC, Dahan R, Reiter Y, Mooney JL, Offner H, Burrows GG.

J Autoimmun. 2013 Feb;40:96-110. doi: 10.1016/j.jaut.2012.08.004. Epub 2012 Sep 29.

15.

Mixed alkanethiol monolayers on submicrometric gold patterns: a controlled platform for studying cell-ligand interactions.

Fishler R, Artzy-Schnirman A, Peer E, Wolchinsky R, Brener R, Waks T, Eshhar Z, Reiter Y, Sivan U.

Nano Lett. 2012 Sep 12;12(9):4992-6. doi: 10.1021/nl302619p. Epub 2012 Aug 21.

PMID:
22900991
16.

Melanoma cells present high levels of HLA-A2-tyrosinase in association with instability and aberrant intracellular processing of tyrosinase.

Michaeli Y, Sinik K, Haus-Cohen M, Reiter Y.

Eur J Immunol. 2012 Apr;42(4):842-50. doi: 10.1002/eji.201141511.

17.

T-cell-receptor-like antibodies - generation, function and applications.

Dahan R, Reiter Y.

Expert Rev Mol Med. 2012 Feb 24;14:e6. doi: 10.1017/erm.2012.2. Review.

PMID:
22361332
18.

Electrically controlled molecular recognition harnessed to activate a cellular response.

Artzy-Schnirman A, Blat D, Talmon Y, Fishler R, Gertman D, Oren R, Wolchinsky R, Waks T, Benhar I, Eshhar Z, Sivan U, Reiter Y.

Nano Lett. 2011 Nov 9;11(11):4997-5001. doi: 10.1021/nl202971r. Epub 2011 Oct 21.

PMID:
21985491
19.

TCR-like antibodies distinguish conformational and functional differences in two- versus four-domain auto reactive MHC class II-peptide complexes.

Dahan R, Tabul M, Chou YK, Meza-Romero R, Andrew S, Ferro AJ, Burrows GG, Offner H, Vandenbark AA, Reiter Y.

Eur J Immunol. 2011 May;41(5):1465-79. doi: 10.1002/eji.201041241. Epub 2011 Apr 12.

20.

Therapeutic antibodies: Discovery and development using the ProteOn XPR36 biosensor interaction array system.

Bronner V, Denkberg G, Peled M, Elbaz Y, Zahavi E, Kasoto H, Reiter Y, Notcovich A, Bravman T.

Anal Biochem. 2010 Nov 15;406(2):147-56. doi: 10.1016/j.ab.2010.07.005. Epub 2010 Aug 3.

PMID:
20624370
21.

Cross-priming CD8+ T cells by targeting antigens to human dendritic cells through DCIR.

Klechevsky E, Flamar AL, Cao Y, Blanck JP, Liu M, O'Bar A, Agouna-Deciat O, Klucar P, Thompson-Snipes L, Zurawski S, Reiter Y, Palucka AK, Zurawski G, Banchereau J.

Blood. 2010 Sep 9;116(10):1685-97. doi: 10.1182/blood-2010-01-264960. Epub 2010 Jun 7.

22.

Direct visualization of the dynamics of antigen presentation in human cells infected with cytomegalovirus revealed by antibodies mimicking TCR specificity.

Makler O, Oved K, Netzer N, Wolf D, Reiter Y.

Eur J Immunol. 2010 Jun;40(6):1552-65. doi: 10.1002/eji.200939875.

23.

Expression hierarchy of T cell epitopes from melanoma differentiation antigens: unexpected high level presentation of tyrosinase-HLA-A2 Complexes revealed by peptide-specific, MHC-restricted, TCR-like antibodies.

Michaeli Y, Denkberg G, Sinik K, Lantzy L, Chih-Sheng C, Beauverd C, Ziv T, Romero P, Reiter Y.

J Immunol. 2009 May 15;182(10):6328-41. doi: 10.4049/jimmunol.0801898.

24.

Predicting and controlling the reactivity of immune cell populations against cancer.

Oved K, Eden E, Akerman M, Noy R, Wolchinsky R, Izhaki O, Schallmach E, Kubi A, Zabari N, Schachter J, Alon U, Mandel-Gutfreund Y, Besser MJ, Reiter Y.

Mol Syst Biol. 2009;5:265. doi: 10.1038/msb.2009.15. Epub 2009 Apr 28.

25.

Modifying interleukin-2 concentrations during culture improves function of T cells for adoptive immunotherapy.

Besser MJ, Schallmach E, Oved K, Treves AJ, Markel G, Reiter Y, Schachter J.

Cytotherapy. 2009;11(2):206-17. doi: 10.1080/14653240802590391.

PMID:
19148842
26.

Presentation of telomerase reverse transcriptase, a self-tumor antigen, is down-regulated by histone deacetylase inhibition.

Pellicciotta I, Cortez-Gonzalez X, Sasik R, Reiter Y, Hardiman G, Langlade-Demoyen P, Zanetti M.

Cancer Res. 2008 Oct 1;68(19):8085-93. doi: 10.1158/0008-5472.CAN-08-1014.

27.

Functional specializations of human epidermal Langerhans cells and CD14+ dermal dendritic cells.

Klechevsky E, Morita R, Liu M, Cao Y, Coquery S, Thompson-Snipes L, Briere F, Chaussabel D, Zurawski G, Palucka AK, Reiter Y, Banchereau J, Ueno H.

Immunity. 2008 Sep 19;29(3):497-510. doi: 10.1016/j.immuni.2008.07.013.

28.

A two-state electronic antigen and an antibody selected to discriminate between these states.

Artzy-Schnirman A, Brod E, Epel M, Dines M, Hammer T, Benhar I, Reiter Y, Sivan U.

Nano Lett. 2008 Oct;8(10):3398-403. doi: 10.1021/nl8020895. Epub 2008 Sep 13.

PMID:
18788790
29.

Antitumor activity of immunotoxins with T-cell receptor-like specificity against human melanoma xenografts.

Klechevsky E, Gallegos M, Denkberg G, Palucka K, Banchereau J, Cohen C, Reiter Y.

Cancer Res. 2008 Aug 1;68(15):6360-7. doi: 10.1158/0008-5472.CAN-08-0928.

30.

The exception that reinforces the rule: crosspriming by cytosolic peptides that escape degradation.

Lev A, Takeda K, Zanker D, Maynard JC, Dimberu P, Waffarn E, Gibbs J, Netzer N, Princiotta MF, Neckers L, Picard D, Nicchitta CV, Chen W, Reiter Y, Bennink JR, Yewdell JW.

Immunity. 2008 Jun;28(6):787-98. doi: 10.1016/j.immuni.2008.04.015.

31.

Cutting edge: MHC class I-Ly49 interaction regulates neuronal function.

Zohar O, Reiter Y, Bennink JR, Lev A, Cavallaro S, Paratore S, Pick CG, Brooker G, Yewdell JW.

J Immunol. 2008 May 15;180(10):6447-51.

32.

Targeting TARP, a novel breast and prostate tumor-associated antigen, with T cell receptor-like human recombinant antibodies.

Epel M, Carmi I, Soueid-Baumgarten S, Oh S, Bera T, Pastan I, Berzofsky J, Reiter Y.

Eur J Immunol. 2008 Jun;38(6):1706-20. doi: 10.1002/eji.200737524.

33.

Phage display of single-chain antibody constructs.

Benhar I, Reiter Y.

Curr Protoc Immunol. 2002 May;Chapter 10:Unit 10.19B. doi: 10.1002/0471142735.im1019bs48.

PMID:
18432867
34.

Phage display-derived recombinant antibodies with TCR-like specificity against alpha-galactosylceramide and its analogues in complex with human CD1d molecules.

Denkberg G, Stronge VS, Zahavi E, Pittoni P, Oren R, Shepherd D, Salio M, McCarthy C, Illarionov PA, van der Merwe A, Besra GS, Dellabona P, Casorati G, Cerundolo V, Reiter Y.

Eur J Immunol. 2008 Mar;38(3):829-40. doi: 10.1002/eji.200737518.

35.

Novel antibodies as anticancer agents.

Zafir-Lavie I, Michaeli Y, Reiter Y.

Oncogene. 2007 May 28;26(25):3714-33. Review.

PMID:
17530025
36.

The length of lipids bound to human CD1d molecules modulates the affinity of NKT cell TCR and the threshold of NKT cell activation.

McCarthy C, Shepherd D, Fleire S, Stronge VS, Koch M, Illarionov PA, Bossi G, Salio M, Denkberg G, Reddington F, Tarlton A, Reddy BG, Schmidt RR, Reiter Y, Griffiths GM, van der Merwe PA, Besra GS, Jones EY, Batista FD, Cerundolo V.

J Exp Med. 2007 May 14;204(5):1131-44. Epub 2007 May 7.

37.

A novel postpriming regulatory check point of effector/memory T cells dictated through antigen density threshold-dependent anergy.

Oved K, Ziv O, Jacob-Hirsch J, Noy R, Novak H, Makler O, Galit D, Keren S, Segal D, Gefen-Dor C, Amariglio N, Rechavi G, Reiter Y.

J Immunol. 2007 Feb 15;178(4):2307-17.

38.
39.

Efficiency of peptide presentation by dendritic cells compared with other cell types: implications for cross-priming.

Zehn D, Cohen CJ, Reiter Y, Walden P.

Int Immunol. 2006 Dec;18(12):1647-54. Epub 2006 Oct 11.

PMID:
17035346
40.

Antibody molecules discriminate between crystalline facets of a gallium arsenide semiconductor.

Artzy Schnirman A, Zahavi E, Yeger H, Rosenfeld R, Benhar I, Reiter Y, Sivan U.

Nano Lett. 2006 Sep;6(9):1870-4.

PMID:
16967993
41.

Preventive and therapeutic vaccination with PAP-3, a novel human prostate cancer peptide, inhibits carcinoma development in HLA transgenic mice.

Machlenkin A, Azriel-Rosenfeld R, Volovitz I, Vadai E, Lev A, Paz A, Goldberger O, Reiter Y, Tzehoval E, Benhar I, Eisenbach L.

Cancer Immunol Immunother. 2007 Feb;56(2):217-26. Epub 2006 Jun 1.

PMID:
16738849
42.

Recombinant antibodies with T-cell receptor-like specificity: novel tools to study MHC class I presentation.

Denkberg G, Reiter Y.

Autoimmun Rev. 2006 Apr;5(4):252-7. Epub 2005 Aug 8. Review.

PMID:
16697965
43.

The influence of a human embryonic stem cell-derived microenvironment on targeting of human solid tumor xenografts.

Tzukerman M, Rosenberg T, Reiter I, Ben-Eliezer S, Denkberg G, Coleman R, Reiter Y, Skorecki K.

Cancer Res. 2006 Apr 1;66(7):3792-801.

44.

Antibodies and their fragments as anti-cancer agents.

Schaedel O, Reiter Y.

Curr Pharm Des. 2006;12(3):363-78. Review.

PMID:
16454750
45.

T-cell receptor-like antibodies: novel reagents for clinical cancer immunology and immunotherapy.

Noy R, Eppel M, Haus-Cohen M, Klechevsky E, Mekler O, Michaeli Y, Denkberg G, Reiter Y.

Expert Rev Anticancer Ther. 2005 Jun;5(3):523-36. Review.

PMID:
16250828
46.
48.
49.

Dissecting cytotoxic T cell responses towards the NY-ESO-1 protein by peptide/MHC-specific antibody fragments.

Held G, Matsuo M, Epel M, Gnjatic S, Ritter G, Lee SY, Tai TY, Cohen CJ, Old LJ, Pfreundschuh M, Reiter Y, Hoogenboom HR, Renner C.

Eur J Immunol. 2004 Oct;34(10):2919-29.

50.

Tumor-specific Ab-mediated targeting of MHC-peptide complexes induces regression of human tumor xenografts in vivo.

Lev A, Noy R, Oved K, Novak H, Segal D, Walden P, Zehn D, Reiter Y.

Proc Natl Acad Sci U S A. 2004 Jun 15;101(24):9051-6. Epub 2004 Jun 7.

Supplemental Content

Loading ...
Support Center